-+ 0.00%
-+ 0.00%
-+ 0.00%

ImmunoPrecise Announces Benchmarking Results For LENSai Epitope Mapping

Benzinga·05/12/2025 12:11:05
Listen to the news

ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, is pleased to announce today new benchmarking results that validate the accuracy and utility of its in silico epitope mapping application, part of the LENSai™ platform, with a direct comparison to gold-standard wet-lab methods.

The results represent a notable advancement in computational biology, particularly in the field of antibody discovery, where high failure rates and costly, time-intensive experiments remain common industry challenges. LENSai's AI-powered platform was able to match the performance of x-ray crystallography—the industry's most precise but slowest and most expensive method—using sequence data alone.